Synlogic Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

Synlogic to Present at Chardan's Virtual Microbiome Medicines Summit

Synlogic Announces Fourth Quarter and Full Year 2019 Conference Call and Webcast

Synlogic Announces Participation in Upcoming Investor Conferences

Synlogic Appoints Dr. Michael Burgess to its Board of Directors

Synlogic Outlines Upcoming Milestones for Clinical Programs and Unveils New Preclinical Pipeline Programs

Synlogic Bridging Study Data with Solid Oral Formulation of SYNB1618, a Synthetic Biotic Approach to Treat Phenylketonuria, Demonstrate Improved Tolerability over Early Liquid Formulation and Guide to Next Stage of Clinical Development

Synlogic to Webcast Presentation at the Piper Jaffray 31st Annual Healthcare Conference

Synlogic Provides Program and Business Update and Reports Third Quarter 2019 Financial Results

Synlogic Announces Third Quarter 2019 Conference Call and Webcast

Synlogic to Present at the Chardan 3rd Annual Genetic Medicines Conference

Synlogic Announces Appointments of New CMO, Head of Regulatory Affairs, and CFO Departure